Alle Storys
Folgen
Keine Story von Novo Nordisk mehr verpassen.

Novo Nordisk

Novo Nordisk Extends Programme for Children With Diabetes in Developing Countries

Denmark (ots/PRNewswire)

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes(R) in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.

To view the Multimedia News Release, please click:

http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes

A child in sub-Saharan Africa diagnosed with type 1 diabetes often has a life expectancy of less than a year[1]. As a response to this situation and as a call to action by the International Diabetes Federation, Novo Nordisk established the Changing Diabetes(R) in Children programme.

The idea originated from a visit to a district hospital in Kenya by Lars Rebien Sorensen, CEO of Novo Nordisk. At the hospital, he met a Masai boy diagnosed with type 1 diabetes who had been deserted by his parents at a highway and taken to the hospital by some passers-by. "It became clear to me that this boy had dire perspectives for staying alive," says Lars Rebien Sorensen. "This is obviously hugely disturbing to anyone that has any way of influencing the situation."

In Guinea, almost 400 children have been enrolled in the programme: "Before we had the programme for children with diabetes in Guinea, the situation was very difficult. Many children diagnosed with diabetes had no access to treatment or stopped it because their parents could not afford to buy insulin," explains Professor Naby Balde, project partner at Donka University Hospital in Conakry, Guinea. "It's great progress for the children and their families; they will no longer have to choose between providing food for the family or treatment of one child."

The Changing Diabetes(R) in Children programme will run until 2017 in order to consolidate the work that has been done and to strengthen the sustainability of the programme in each country.

1. Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043

About Changing Diabetes(R) in Children

The programme is run as a private-public partnership between Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each country (Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Tanzania and Uganda, Bangladesh and India), the programme is implemented by a group of local partners with the national Ministry of Health playing a key role to ensure that the programme is anchored within the existing healthcare system.

Being part of the programme means that each child receives insulin free of charge along with strips and a glucometer to measure his blood sugar levels. But since type 1 diabetes is a chronic condition which needs to be monitored closely, insulin does not do it alone. Therefore, patient education for children and families and training of healthcare personnel is an essential part.

Further information
Charlotte Zarp-Andersson
+45-4442-7603 
czpa@novonordisk.com

(Logo: http://photos.prnewswire.com/prnh/20120911/559804 )


Photo: 
http://photos.prnewswire.com/prnh/20120911/559804

Video: 
http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes

Weitere Storys: Novo Nordisk
Weitere Storys: Novo Nordisk
  • 14.11.2014 – 08:02

    Tianjin and Shanghai Join Cities Changing Diabetes on World Diabetes Day

    Bagsværd, Denmark (ots/PRNewswire) - Today, on World Diabetes Day, the Chinese cities of Tianjin and Shanghai join the Cities Changing Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in ...

  • 12.05.2014 – 11:55

    NovoEight® provides long-term reduction of bleeding in people with haemophilia A

    Copenhagen, Denmark (ots/PRNewswire) - For healthcare media only, not for US, UK or Spanish journalists Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term ...

  • 28.03.2014 – 10:12

    Novo Nordisk Launches 'Cities Changing Diabetes' to Fight Urban Diabetes

    Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge. The 'Cities Changing Diabetes' programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow. To view the Multimedia News Release, ...